meta|evidence oncology
  • Living systematic review and meta-analysis
  • All
  •   AKT inhibitor
  • capivasertib based treatment
  • capivasertib
  • capivasertib plus paclitaxel
  •   antibody–drug conjugate
  • sacituzumab govitecan
  • trastuzumab deruxtecan
  • trastuzumab emtansine
  • trastuzumab emtasine plus pertuzumab
  •   cyclin inhibitor
  •   poly ADP-ribose polymerase (PARP) inhibitor
  • niraparib
  • olaparib
  • rucaparib
  • talazoparib
  • veliparib plus paclitaxel plus carboplatin
  •   VEGF(R) inhibitor